Braun Stacey Associates’s AbbVie ABBV Stock Holding History

Braun Stacey Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22M	Buy	87,528 +3,269	+4%	+$703K	0.62%	66
2026 Q1	$18.3M	Buy	84,259 +1,471	+2%	+$326K	0.61%	72
2025 Q4	$18.9M	Buy	82,788 +1,343	+2%	+$306K	0.61%	72
2025 Q3	$18.9M	Buy	81,445 +1,134	+1%	+$231K	0.62%	72
2025 Q2	$14.9M	Buy	80,311 +1,641	+2%	+$305K	0.54%	78
2025 Q1	$16.5M	Buy	+78,670	New	+$15.3M	0.67%	63
2024 Q3	–	Sell	-4,949	Closed	-$849K	–	115
2024 Q2	$849K	Buy	+4,949	New	+$820K	0.03%	101
2023 Q1	–	Sell	-73,762	Closed	-$11.9M	–	127
2022 Q4	$11.9M	Sell	73,762 -9,773	-12%	-$1.5M	0.68%	71
2022 Q3	$11.2M	Sell	83,535 -17,911	-18%	-$2.57M	0.68%	74
2022 Q2	$15.5M	Sell	101,446 -23,058	-19%	-$3.52M	0.89%	49
2022 Q1	$20.2M	Sell	124,504 -11,815	-9%	-$1.72M	0.84%	52
2021 Q4	$18.5M	Buy	136,319 +2,082	+2%	+$246K	0.67%	71
2021 Q3	$14.5M	Sell	134,237 -4,347	-3%	-$497K	0.58%	86
2021 Q2	$15.6M	Buy	138,584 +525	+0.4%	+$59.1K	0.61%	83
2021 Q1	$14.9M	Buy	138,059 +4,048	+3%	+$433K	0.63%	81
2020 Q4	$14.4M	Buy	134,011 +25,174	+23%	+$2.42M	0.64%	77
2020 Q3	$9.53M	Buy	108,837 +2,932	+3%	+$276K	0.51%	90
2020 Q2	$10.4M	Buy	105,905 +70,420	+198%	+$6.2M	0.6%	86
2020 Q1	$2.7M	Sell	35,485 -900	-2%	-$76.7K	0.21%	99
2019 Q4	$3.22M	Buy	+36,385	New	+$3.02M	0.18%	99
2019 Q2	–	Sell	-4,340	Closed	-$350K	–	115
2019 Q1	$350K	Sell	4,340 -30,035	-87%	-$2.46M	0.02%	112
2018 Q4	$3.17M	Sell	34,375 -79,301	-70%	-$6.97M	0.25%	100
2018 Q3	$10.8M	Sell	113,676 -16,196	-12%	-$1.54M	0.69%	75
2018 Q2	$12M	Buy	129,872 +3,732	+3%	+$364K	0.82%	64
2018 Q1	$11.9M	Sell	126,140 -743	-0.6%	-$81.6K	0.82%	69
2017 Q4	$12.3M	Buy	126,883 +84,908	+202%	+$8M	0.82%	67
2017 Q3	$3.73M	Buy	41,975 +6,810	+19%	+$518K	0.26%	101
2017 Q2	$2.55M	Sell	35,165 -27,269	-44%	-$1.83M	0.17%	105
2017 Q1	$4.07M	Sell	62,434 -150,098	-71%	-$9.44M	0.26%	103
2016 Q4	$13.3M	Sell	212,532 -39,095	-16%	-$2.39M	0.87%	55
2016 Q3	$15.9M	Sell	251,627 -6,425	-2%	-$416K	1.01%	46
2016 Q2	$16M	Sell	258,052 -21,884	-8%	-$1.33M	1.03%	45
2016 Q1	$16M	Sell	279,936 -9,669	-3%	-$539K	1.04%	41
2015 Q4	$17.2M	Buy	289,605 +57,185	+25%	+$3.29M	1.08%	37
2015 Q3	$12.6M	Buy	232,420 +223,895	+2,626%	+$14.6M	0.85%	63
2015 Q2	$573K	Buy	8,525 +200	+2%	+$13.1K	0.02%	225
2015 Q1	$487K	Buy	8,325 +700	+9%	+$42.3K	0.03%	117
2014 Q4	$499K	Hold	7,625	–	–	0.03%	119
2014 Q3	$440K	Hold	7,625	–	–	0.03%	120
2014 Q2	$430K	Buy	7,625 +3,300	+76%	+$173K	0.03%	118
2014 Q1	$222K	Buy	+4,325	New	+$219K	0.01%	146

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Braun Stacey Associates's ABBV Position: Q2 2026 in Review

Braun Stacey Associates increased its AbbVie (ABBV) stake by 3.9% in Q2 2026, buying an estimated $703K and bringing the position to 87,528 shares worth $22M. The position accounts for 0.62% of the portfolio, ranked #66.

Braun Stacey Associates first reported a position in ABBV in Q1 2014 and has held it in 41 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Braun Stacey Associates held 87,528 shares of AbbVie worth $22M as of Q2 2026.
Braun Stacey Associates bought 3,269 AbbVie shares in Q2 2026, an estimated $703K.
AbbVie made up 0.62% of Braun Stacey Associates's portfolio in Q2 2026, its #66 holding.
Braun Stacey Associates first reported a position in AbbVie in Q1 2014 and has held it in 41 quarters since.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Braun Stacey Associates's 13F filing for Q2 2026, filed 5 Aug 2026.